APEX Breast01
TQB2102 (biapotropic ADC against HER2 with topo1 payload)
Rolditamig Deuderuxtecan (TQB2102) vs TPC Chemo in HER2low MBC, no prior chemo (461 HR+, 81 TNBC)
PFS HER2low: 16.4 vs 5.5 mo, HR 0.29
ILD 1.1%

@OncoAlert #ESMO2026